Cabozantinib (average 1.68-fold) and axitinib (average 1.65-fold), which increased trogocytosis as monotherapy, further elevated trogocytosis when used in combination with anti-CD47 blocking antibody in most RCC cell lines. This evidence concerns the gene CD47 and renal cell carcinoma.